Sign in
Not yet recruitingNo phase

Platelet-rich fibrin added to surgery for jaw bone damage caused by medicines

Tests adding L-PRF to surgery for medication-related osteonecrosis of the jaw, looking at wound healing.

Key facts

Who runs it
University Hospital, Toulouse
Where
France6 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw
Status
Not yet recruiting
People taking part
150 people, planned
Started
Nov 2026
Expected to end
May 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Surgery with the use of L-PRF
  • Standard surgery
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with jaw bone damage caused by medicines (MRONJ) who need surgery under general anesthesia. It tests L-PRF, a material made from the patient's own blood, added to surgery.

Age
18 Years and older
Sex
All
Disease stage
MRONJ stage 2 or 3 by AAOMS criteria, with a dead bone piece that must be removed under general anesthesia.
Earlier treatment
First-line treatments must have failed.

Main reasons for not taking part

  • A tumour in the upper or lower jaw
  • More than one MRONJ lesion
  • Past radiotherapy to the head and neck
  • Cannot have general anesthesia
  • Life expectancy estimated at less than 6 months

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • MRONJ requiring surgical treatment according to AAOMS criteria (stage 2 or 3; failure of first-line treatments; sequestration of a necrotic bone block), the resection of which needs general anesthesia
  • Affiliates or beneficiaries of a social security scheme
  • Having given free and informed written consent

Who cannot take part

  • History of cervico-facial radiotherapy
  • Presence of a maxillo-mandibular neoplastic lesion
  • Presence of several MRONJ lesions
  • Contraindication to general anesthesia
  • Reduced life expectancy (estimated at less than 6 months)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious side-effect of antiresorptive therapies used in the management of bone diseases, such as osteoporosis or bone metastases. A surgical management can lead to a resolution of the disease, but with perfectible results. For this purpose, the use of autologous platelet concentrates (APC) can be useful. With this study, researchers aim to demonstrate the efficacy of L-PRF (Leukocyte- and Platelet-Rich Fibrin) as an adjunct to the surgical treatment of MRONJ in terms of wound healing.

The 2 groups in the trial

  • Experimental groupTreatment being tested

    Patients will benefit from surgery with the use of L-PRF.

    Treatment: Surgery with the use of L-PRF

  • Control groupOther group

    Patients will benefit from standard surgical treatment.

    Treatment: Standard surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Use of Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw: a Randomized Controlled Trial
Plain-language title
Platelet-rich fibrin added to surgery for jaw bone damage caused by medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
29 October 2026